Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
Status:
Active, not recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This study will describe the safety of furosemide in premature infants at risk of
bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics
(PK) of furosemide. Funding Source - FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Duke University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) The Emmes Company, LLC The EMMES Corporation